Twin Tree Management LP Sells 112,153 Shares of Boston Scientific Corporation $BSX

Key Points

• Twin Tree Management LP significantly reduced its investment in Boston Scientific Corporation by 87.6%, selling 112,153 shares and now holding only 15,923 shares valued at approximately $1.6 million.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, surpassing analyst estimates of $0.72, alongside a revenue of $5.06 billion for the quarter.
• Insider transactions revealed that directors Edward J. Ludwig and Yoshiaki Fujimori sold a total of 6,901 shares, reflecting substantial decreases in their positions of 17.79% and 58.23%, respectively.

Twin Tree Management LP cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 87.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,923 shares of the medical equipment provider's stock after selling 112,153 shares during the quarter. Twin Tree Management LP's holdings in Boston Scientific were worth $1,606,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. NS Partners Ltd raised its holdings in Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after acquiring an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after purchasing an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Boston Scientific in the 1st quarter worth $8,234,000. Finally, Blue Trust Inc. increased its holdings in shares of Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after purchasing an additional 575 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $18,397,457 over the last 90 days. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research analyst reports. Morgan Stanley increased their price target on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Raymond James Financial increased their price target on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Barclays boosted their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Robert W. Baird boosted their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Price Performance

Shares of BSX stock traded down $0.15 on Friday, hitting $107.14. 4,062,436 shares of the stock traded hands, compared to its average volume of 5,787,252. The firm has a market cap of $158.76 billion, a price-to-earnings ratio of 63.78, a PEG ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $108.94. The firm has a 50 day simple moving average of $104.77 and a two-hundred day simple moving average of $102.20. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.